Trials / Active Not Recruiting
Active Not RecruitingNCT05735496
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
A Phase I Study of TQB2102 Injection in Patients With Advanced Cancers
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB102 injection in subjects with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2102 injection | TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload. |
Timeline
- Start date
- 2023-03-09
- Primary completion
- 2025-07-21
- Completion
- 2027-07-01
- First posted
- 2023-02-21
- Last updated
- 2025-08-01
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05735496. Inclusion in this directory is not an endorsement.